✦ LIBER ✦

OP2. Cost-effectiveness analysis of paclitaxel and cisplatinum versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer — A European perspective

✍ Scribed by K Berger; T Szucs

Book ID: 117665249
Publisher: Elsevier Science
Year: 1997
Tongue: English
Weight: 174 KB
Volume: 33
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(97)85881-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness analysis of paclitaxe

Cost-effectiveness analysis of paclitaxel and cisplatin versus cyclophosphamide and cisplatin as first-line therapy in advanced ovarian cancer. A European perspective

✍ K. Berger; T. Fischer; T.D. Szucs 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 81 KB

CH1: COST-EFFECTIVENESS ANALYSIS OF IRIN

CH1: COST-EFFECTIVENESS ANALYSIS OF IRINOTECAN AS FIRST-LINE THERAPY IN ADVANCED COLORECTAL CANCER

✍ C Schmitt; C Levy-Piedbois; M Frappe; I Durand-Zaleski 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 54 KB

Pharmacoeconomic profile of paclitaxel a

Pharmacoeconomic profile of paclitaxel as a first-line treatment for patients with advanced ovarian carcinoma : A lifetime cost-effectiveness analysis

✍ Andrea Messori; Michele Cecchi; Paola Becagli; Sabrina Trippoli 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 2 views

medullary recurrence in certain ethnic groups will be the field have read the article. I agree that there is no proof that all-trans retinoic acid (ATRA) therapy confirmed by further observation and analysis of recurrence in the large cooperative group studying APL. predisposes patients to the deve

Phase I Trial of Carboplatin, Paclitaxel

Phase I Trial of Carboplatin, Paclitaxel, Etoposide, and Cyclophosphamide with Granulocyte Colony Stimulating Factor as First-Line Therapy for Patients with Advanced Epithelial Ovarian Cancer

✍ Nadine Tung; Ross Berkowitz; Ursula Matulonis; Marc Quartulli; Michael Seiden; Y 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 56 KB

740 POSTER Fluorouracil, leucovorin and

740 POSTER Fluorouracil, leucovorin and oxaliplatin (FLO) versus fluorouracil, leucovorin and cisplatin (FLP) as a first line therapy in patients with advanced gastric cancer —interim analysis of a multicenter, randomized phase II trial

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 302 KB

PCN116 A SURVIVAL BASED COST-EFFECTIVENE

PCN116 A SURVIVAL BASED COST-EFFECTIVENESS ANALYSIS OF 5 YEARS LETROZOLE VERSUS TAMOXIFEN AS ADJUVANT THERAPY IN POSTMENOPAUSAL WOMEN WITH EARLY BREAST CANCER: CANADIAN PERSPECTIVE

✍ K El Ouagari; S Kaura; JD Karnon 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB